The use of targeted nanoparticles offers promising techniques for cancer treatment. Researchers in the laboratory of Mark E. Davis at the California Institute of Technology have been using small ...
Effective targeted therapies against aggressive breast cancer subtypes, such as triple-negative breast cancer (TNBC), are still lacking. Developing therapeutics targeting nonenzymatic, intracellular ...
King of Prussia, Pennsylvania--(Newsfile Corp. - November 7, 2025) - Phio Pharmaceuticals Corp. (PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary ...
株式会社レトリバ（本社：東京都新宿区、代表取締役 田口琢也）は、かねてよりAI技術をバイオ領域で活用してきました。高速塩基配列検索ソフトウェア 「GGGenome(ゲゲゲノム)※1パッケージ版」 は核酸医薬品の安全性評価において信頼と実績もっています。
SAN ANTONIO, Texas, June 24, 2025--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage diagnostics and targeted therapeutics for cancer ...
SAN ANTONIO, Texas--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage diagnostics and targeted therapeutics for cancer, today ...
Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) King of Prussia, Pennsylvania--(Newsfile Corp. - November 7, 2025) - Phio Pharmaceuticals Corp. (NASDAQ ...
King of Prussia, Pennsylvania--(Newsfile Corp. - November 7, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する